TeamDrive
RUS

Interdepartmental Commission has approved NovaMedicas application for conclusion of SPIC aimed at creation of a new pharmaceutical manufacturing facility

22 December 2017

Moscow, December 22, 2017 – Russian pharmaceutical company NovaMedica (investment project of Rusnano) informed that it received approval of the Interdepartmental Committee (IDC) to conclude the Special Investment Contract (SPIC) within the investment project devoted to creation of a pharmaceutical plant for manufacturing of sterile injectable drug products in the Kaluga region. This is the first SPIC in the industry which is aimed at support of creation of a greenfield pharmaceutical facility. 

Portfolio of drug products which was supported by the IDC includes essential drugs which were transferred to NovaMedica within its partnership with Pfizer as well as own development products of NovaMedica. SPIC envisages extension of this list with the development of the pipeline of own R&D products of NovaMedica subject to approval of the IDC. Company plans to manufacture more than 40 modern effective drug products which are demanded by the Russian patients. 

“Creation of a greenfield high-tech pharmaceutical manufacturing facility in full compliance with international standards of quality will allow us to provide Russian patients with effective drug products and will open an opportunity to export our products abroad. SPIC is highly important for us. We greatly appreciate support of the Ministry of Industry and Trade of the Russian Federation and Administration of the Kaluga region where our plant is going to be constructed as well as of our strategic partner – Pfizer which transfers to us valuable knowledge and technologies of manufacturing of modern highly-demanded drug products”, noted Alexander Kuzin, CEO of NovaMedica

SPIC will include main measures of stimulation of development of pharmaceutical manufacturing in Russia by providing the status of local manufacturer as well as of the right to receive the status of unique supplier of a wide range of essential drug products in order to participate in the process of state procurement. Term of the SPIC is until 2026. It is planned that the Contract will be signed in the next couple of months. 

About NovaMedica

NovaMedica is a modern Russian pharmaceutical company founded in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RUSNANO, JSC. NovaMedica possesses a well-developed infrastructure for promotion and sales of pharmaceutical products. Currently company is promoting a portfolio of 25 ophthalmological and gastroenterological products in the Russian market. NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceuticals products and technologies, as well as at development and implementation of own R&D projects. In April 2017 NovaMedica opened the Technological Center with state-of-the-art technological capabilities which were previously unavailable in the Russian pharmaceutical industry. NovaMedica became key partner of Pfizer in Russia in 2016. Within this partnership NovaMedica started construction of the pharmaceutical GMP manufacturing facility in the Kaluga region in May 2017. In October 2017 R&D Center of NovaMedica received a manufacturing license from the Ministry of industry and Trade of the Russian Federation. In December 2017 Interdepartmental Commission approved NovaMedica’s application for SPIC to create new pharmaceutical manufacturing facility in the Kaluga region.

More information at www.novamedica.com, follow us on Facebook and LinkedIn.


Previous publication Next publication

Media Center

  • 23 October 2018

    Genomic Health Announces Multiple Studies Reinforcing Value of Oncotype DX Tests in Guiding Treatment for Breast and Prostate Cancer Patients

    Genomic Health, Inc. (Nasdaq: GHDX) today announced results from multiple studies of its Oncotype DX® tests highlighting their value in optimizing treatment for patients with various stages of breast and prostate cancer. The findings, presented at the ESMO 2018 Congress in Munich, Germany, demonstrated that the Oncotype DX tests identify patients who will or will not benefit from a specific treatment.

  • 23 October 2018

    Russian cancer drug based on smallpox vaccine undergoes preclinical studies

    Siberian scientists have brought to the final stage of preclinical testing the only Russian therapeutic cancer drug. This part of the study is expected to be completed by the end of 2019, according to Sergei Netesov, Chairman of the Board of the Association for the Development of the Innovative Territorial Cluster of the Novosibirsk Region in the Sphere of Biopharmaceutical Technologies (‘Biopharm’).

  • 22 October 2018

    Pfizer preps for BMS showdown with Bavencio kidney cancer combo data

    Pfizer has long been a player in kidney cancer, but it’s looking to take things up a notch—and challenge next-gen rival Bristol-Myers Squibb—with its latest data. Sunday at the European Society for Medical Oncology annual meeting, the New York drugmaker and partner Merck KGaA said their immuno-oncology agent Bavencio, in tandem with Pfizer’s Inlyta, had staved off cancer progression in previously untreated patients by a median 13.8 months, compared with 8.4 months for standard-of-care Sutent, another Pfizer drug.

  • 19 October 2018

    FDA Publishes Guidance on the Rare Disease Treatments

    FDA published draft guidance on October 15, 2018 to assist sponsors developing treatments for rare diseases plan for pre-investigational new drug application (pre-IND) meetings with FDA. In the guidance, the agency describes topics that should be considered in early drug development and pre-IND meetings.

Read more